Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

ClinicalTrials.gov ID: NCT04292223

Public ClinicalTrials.gov record NCT04292223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

Study identification

NCT ID: NCT04292223
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Enrollment: 29 participants

Conditions and interventions

Conditions

Parkinson Disease Psychosis

Interventions

Pimavanserin Drug

Drug

Eligibility (public fields only)

Age range: 40 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 10, 2020 (Actual)
Primary completion: Apr 26, 2022 (Actual)
Completion: Apr 26, 2022 (Actual)
Last update posted: Jan 14, 2025

2020 – 2022

United States locations

U.S. sites: 18
U.S. states: 11
U.S. cities: 18

Facility	City	State	ZIP	Site status
Movement Disorders Center of Arizona	Scottsdale	Arizona	85258	—
Neurology Center of North Orange County	Fullerton	California	92835	—
Premier Clinical Research Institute, Inc.	Miami	Florida	33122	—
Global Health Research Center, Inc.	Miami Lakes	Florida	33016	—
Quantum Laboratories, Inc.	Pompano Beach	Florida	33064	—
Parkinson's Disease Treatment Center of Southwest Florida	Port Charlotte	Florida	33980	—
Accel Research Sites - Brain and Spine Institute	Port Orange	Florida	32127	—
Infinity Clinical Research, LLC	Sunrise	Florida	33351	—
Premiere Research Institute at Palm Beach Neurology	West Palm Beach	Florida	33407	—
AU Movement and Memory Disorders	Augusta	Georgia	30912	—
Maine Medical Partners Neurology	Scarborough	Maine	04074	—
Wentworth Health Partners Coastal Neurology Services	Dover	New Hampshire	03820	—
Bio Behavioral Health	Toms River	New Jersey	08755	—
Neurology Diagnostics, Inc.	Dayton	Ohio	45459	—
The Orthopedic Foundation	New Albany	Ohio	43054	—
Central States Research	Tulsa	Oklahoma	74136	—
KCA Neurology	Franklin	Tennessee	37067	—
Neurological Associates of North Texas	Dallas	Texas	75218	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04292223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 14, 2025 · Synced Oct 29, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04292223 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →